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Introduction 
Throughout the past couple of decades, dyslipidemia in pediatrics has been a subject of 
growing concern due to its correlation with both obesity and cardiovascular risk factors. 
Research has shown that if dyslipidemia goes untreated throughout childhood, a child is at an 
increased risk of developing early atherosclerosis, cardiovascular disease, heart attacks, and 
stroke during adulthood (DeFerranti & Newburger, 2017). The American Academy of Pediatrics 
has clinical practice guidelines in place for healthcare providers that outlines when a child should 
undergo dyslipidemia screening. The hope is that through early detection and treatment, a child’s 
morbidity and mortality from cardiovascular disease will be drastically improved down the road.   
There has been a lack of research that examines why dyslipidemia screening rates are 
historically low throughout the pediatric primary care population and what needs to be done to 
address this. It is important that healthcare providers are provided with both education and 
evidence-based research that demonstrates the need behind dyslipidemia screening in childhood. 
The aim of this study is to provide education to healthcare providers at a pediatric primary care 
clinic to increase screening rates and provide children with the best possible preventive care that 
they deserve.  
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Abstract 
PURPOSE: The purpose of this study is to examine the outcome of healthcare provider 
education on the incidence of dyslipidemia screening in a pediatric primary care clinic.  
METHODS: The design of this study was a descriptive pre and post design to evaluate if 
dyslipidemia screening rates, knowledge, and self-efficacy of healthcare providers changed 
following an education series at a general pediatric clinic in Lexington, KY. The rates of 
dyslipidemia screening were calculated prior to providing provider education as well as 
afterwards to see whether there was an improvement in screening rates. Provider’s knowledge 
and confidence before the education series was also assessed via a survey. The sample of this 
study consisted of 11 pediatric healthcare providers at a general pediatric clinic. The secondary 
sample of this study were the medical records of children between the ages of 9 and 11 years 
who presented to a general pediatric clinic for an annual well-child exam. The sample consisted 
of 256 medical records during the pre-education time period, June 2018 to August 2018, and 65 
medical records during the post-education time period, September 10, 2018 to October 19, 2018.  
RESULTS: The Chi-square test of association was used to compare dyslipidemia screening rates 
before and after the educational intervention was given in the pediatric primary care clinic. The 
Chi-square test was also used after the educational burst e-mail was sent to all healthcare 
providers three weeks after the start of the study. Three months prior to the educational 
intervention being implemented, 17.2% of providers performed routine dyslipidemia screening 
on children between the ages of 9-11 years during annual well-child exams. Post-educational 
intervention, dyslipidemia screening rates increased to 24.6% (P=0.1701). An e-mail serving as 
an educational burst was sent to all providers at the clinic three weeks after the start of the study, 
regardless of whether they received education, reminding them of the evidence-based guidelines 
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and the need to screen. Dyslipidemia screening rates increased from 18.75% prior to the e-mail 
to 26.53% after the e-mail was sent (P=0.7409). Lastly, descriptive statistics including means 
and standard deviations were used to summarize healthcare provider’s confidence and 
knowledge in dyslipidemia screening. The results yielded that many healthcare providers do not 
feel confident in the evidence-based guidelines regarding dyslipidemia screening and 
management in the pediatric primary care population nor feel comfortable treating.  
CONCLUSION: Dyslipidemia screening rates improved from 17.2% to 24.6%, an increase of 
43% between the two percentages, at a general pediatric clinic after the educational intervention 
was implemented. This is a significant improvement and evidence that education on the current 
AAP guidelines was needed. Of the providers that participated, 81.8% strongly agreed that they 
felt more confident in when and how to screen, diagnose, and manage dyslipidemia in children 
between the ages of 9 and 11 years after they received education. Providing quality, evidence-
based care is of utmost importance in the clinic. This intervention will likely lead to improved 
early diagnoses and treatment of dyslipidemia in the pediatric population and reduce morbidity 
and mortality in adulthood.  
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Background 
Dyslipidemia is a known risk factor for cardiovascular disease (CVD) that often 
manifests during childhood and adolescence (De Ferranti & Newburger, 2017). Heart disease is 
the leading cause of death for both men and women, contributing to 630,000 deaths each year 
(Cholesterol, 2017). Twenty percent of children in the United States between the ages of 6 and 
19 years have adverse levels of one or more lipid value (De Ferranti & Newburger, 2017). The 
majority of lipid disorders exhibit no signs or symptoms. Therefore, it is crucial that screening be 
conducted on every child regardless of whether there are known risk factors or a family history. 
It is estimated that 50 percent of children with abnormal serum lipoprotein values will continue 
to have elevated lipid levels into adulthood (De Ferranti & Newburger, 2017). The American 
Academy of Pediatrics (AAP) in conjunction with the National Heart Lung and Blood Institute 
(NHLBI) Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction 
in Children and Adolescents endorse that all children between the ages of 9 and 11 years undergo 
dyslipidemia screening before the onset of puberty. Members of the AAP in Utah were surveyed 
by the National Institute of Health in 2011 to assess if they were performing routine dyslipidemia 
screenings on all children seen in clinic between the ages of 9 and 11. Of the 118 respondents 
who practiced primary care, only 15% screened all children at well-child checks (Stipelman et. 
al., 2016). In an evidence report and systematic literature review published by the Journal of the 
American Medical Association (JAMA) in 2016, it was found that current rates of dyslipidemia 
screening in children and adolescents are low, estimated between 2.5% and 3.2% (Lozano et. al, 
2016). These statistics are staggering and a direct indication that this problem in the pediatric 
population needs to be addressed. Through early identification of dyslipidemia, a child’s lipid 
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profile can be improved through lifestyle modifications or medication which reduces their risk of 
developing premature atherosclerosis and CVD in the future (De Ferranti & Newburger, 2017).  
The history of dyslipidemia has been traditionally centered on Familial Heterozygous 
Hypercholesterolemia (FH) which is an inherited, autosomal dominant condition that occurs in 1 
in every 500 individuals (Cook et. al, 2011). However, with childhood obesity rates tripling over 
the past 30 years, there is now a heightened concern for a second and larger population of 
children with dyslipidemia secondary to obesity (Cook et. al., 2011). Pediatric dyslipidemia 
primarily effects children who are overweight (BMI 85th to 95th percentile) and obese (BMI 
>95th percentile) (De Ferranti & Newburger, 2017). In an analysis of National Health and 
Nutrition Examination Survey (NHAMES), it was found that 14% of youths who were normal 
weight, 22% of youths who were overweight, and 43% of youths who were obese had adverse 
lipid levels (De Ferranti & Newburger, 2017). It is estimated that 100,000 children under the age 
of 17 and 400,000 adolescents between the ages of 17 and 21 would qualify for statin therapy in 
the United States based on the current NHBLI and AAP recommendations (De Ferranti & 
Newburger, 2017).  
Dyslipidemia in children is characterized by disorders of lipoprotein metabolism that 
result in the following abnormalities: high total cholesterol, high low-density lipoprotein 
cholesterol, high non-high-density lipoprotein cholesterol, high triglycerides, and low high-
density lipoprotein cholesterol (De Ferranti & Newburger, 2017). Normal lipid values in children 
vary by age and sex. In addition to variance, these values change with normal growth and 
maturation. Therefore, it is critical that screening be done at specific intervals to avoid false 
negatives or positives. Normal lipid and lipoprotein values are measurable and come from a 
collaboration of data collected by the Lipid Research Clinical (LRC) Prevalence Study and from 
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the United States National Health and Nutrition Examination Surveys (De Ferranti & 
Newburger, 2017).  
Public health efforts are now being made to reduce cardiovascular risk factors, such as 
pediatric dyslipidemia, to reduce the overall morbidity and mortality rate of cardiovascular 
disease in the future (Cook et. al., 2011). The World Health Organization reported that there 
were 5.7 million deaths to stroke in 2005 and speculates that this number may reach 23 million 
by 2030 (Kuklina et. al., 2012). According to the CDC, heart disease contributes to 630,000 
deaths each year (Cholesterol, 2017). Early recognition and treatment of pediatric dyslipidemia 
could play a significant part in decreasing the mortality rate of such conditions. 
Purpose 
The purpose of this study was to examine the outcome of healthcare provider education 
on the incidence of dyslipidemia screening at a general pediatric clinic in Lexington, KY. The 
rates of dyslipidemia screening were examined prior to providing education to healthcare 
providers as well as afterwards through a descriptive pre and post design. Provider’s knowledge 
and confidence before the education series was obtained through an anonymous survey. The 
overall goal of this project was to increase screening rates of dyslipidemia in a pediatric primary 
care setting. The objectives of this project are as follows: 
1. Determine baseline dyslipidemia screening rates at the clinic prior to initiating 
education. 
2. Examine dyslipidemia screening rates after education has been given to staff at 1-, 
4- and 6- weeks.  
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3. Measure healthcare provider’s confidence and knowledge in both screening for 
and managing dyslipidemia according to evidence-based guidelines. 
Methods 
Study Design 
 The design of this study was a descriptive pre and post design to evaluate if dyslipidemia 
screening rates, knowledge, and self-efficacy of healthcare provider’s changed following an 
education series at a general pediatric clinic. The rates of dyslipidemia screening were calculated 
prior to providing provider education to see whether there was an improvement in screening 
rates. Provider’s knowledge and confidence before the education series was also obtained after 
receiving informed consent through a survey. 
Setting 
 The setting of this study took place at a general pediatric clinic in Lexington, KY. The 
mission of the organization is to provide leading-edge patient care while advancing professional 
nursing and practice. This clinic serves a primary population of children between the ages of 
birth to 18 years.  
Sample/Participants  
The sample of this study consisted of pediatric healthcare providers who worked at a 
general pediatric clinic in Lexington, KY. The dates of the study were from September 10, 2018 
through October 19, 2018. Healthcare providers were asked to take part in an anonymous survey 
regarding their knowledge and confidence in dyslipidemia screening. The primary care office 
consists of 21 physicians and 4 nurse practitioners. The total sample of the study involved 11 
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pediatric healthcare providers at a general pediatric clinic. The inclusion criteria were as follows: 
any provider who performs a well-child exam for the pediatric population and is willing to 
participate in the survey. The exclusion criteria were: 1) any provider who does not provide care 
for the pediatric population and 2) any provider who is not willing to participate in the survey. 
The secondary subjects of this study were the medical records of children between the 
ages of 9 and 11 years who presented to a general pediatric clinic for an annual well-child exam. 
Two hundred fifty-six medical records were extracted from Allscripts Electronic Health Record 
(AEHR) between June 2018-August 2018 for all children between 9 and 11 years who presented 
to the clinic for an annual well-child exam in order to determine pre-education screening rates. 
Inclusion criteria were as follows: all children between the ages of 9 and 11 years who presented 
to a general pediatric clinic for an annual well-child exam (refer to Table 1 for a comprehensive 
list of ICD-10 and CPT codes used for inclusion criteria). Exclusion criteria consisted of: 1) 
children younger than 9 years or older than 11 years and 2) all children, regardless of age, who 
present to the clinic for an acute visit. Post-education screening rates were examined by 
extracting medical records of children between 9 and 11 years who presented to the clinic for an 
annual well-child exam from AEHR using the inclusion and exclusion criteria listed above 
between the weeks of September 10, 2018 through October 19, 2018. 65 medical records were 
pulled from AEHR for post-education screening rates.  
Data Collection 
Approval from the University of Kentucky Institutional Review Board (IRB) was 
obtained in August 2018 prior to the collection of data. The patient medical records, healthcare 
provider educational materials, and healthcare provider survey were the three tools utilized to 
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assess whether dyslipidemia screening rates were affected at a general pediatric clinic throughout 
the study. The educational materials provided were expected to change healthcare provider 
behavior in terms of dyslipidemia screening in children between the ages of 9 and 11 years by 
increasing awareness and updating them on current clinical practice guidelines endorsed by the 
American Academy of Pediatrics and NHLBI (refer to Table 2 and Figure A). The anonymous 
and voluntary surveys were used to assess whether healthcare providers felt both confident and 
knowledgeable in screening, managing, and treating dyslipidemia in the pediatric primary care 
population (refer to Table 3).  
The primary investigator frequented the general pediatric clinic throughout the post-
education period between September 10, 2018 and October 19, 2018 and provided education and 
surveys to healthcare providers who were present in the office at the time. There are 21 
physicians and 4 nurse practitioners in the primary care clinic who were eligible to take this 
survey. A total of 11 healthcare providers took part in both the education session and anonymous 
survey. An e-mail reminder serving as an educational burst was sent out three weeks after the 
project was started during the week of October 1, 2018, regardless of whether they participated 
in the survey. This e-mail served as a reminder to screen for dyslipidemia (refer to Figure B). 
Since the survey was completely anonymous, there was not a follow-up survey issued after the 
educational series or completion of the project.  
Data Analysis  
The study utilized a descriptive pre and post design. Data Analysis Statistical Package for 
the Social Sciences (SPSS) software was used in the analysis of data. Screening rates were 
calculated into frequencies (%). The Chi-square test of association was used to compare 
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dyslipidemia screening rates before and after the educational intervention was given in the 
pediatric primary care clinic. The Chi-square test was also used after the educational burst e-mail 
was sent to all healthcare providers three weeks after the start of the study. Each anonymous 
survey response completed by healthcare providers was also calculated into frequencies (%). 
Descriptive statistics, including means and standard deviations, were used to summarize 
provider’s confidence and knowledge in dyslipidemia screening. SPSS software, version 24, with 
an alpha level of 0.05 was used for statistical significance throughout analysis.  
Results  
Sample Characteristics  
 There were 256 medical records reviewed during the pre-education period between June 
2018 and August 2018. During the six-week post-education period between September 10, 2018 
and October 19, 2018, there were 65 medical records reviewed. The mean age of children 
screened for dyslipidemia was 9.82 years. Of the 65 medical records reviewed during the post-
education period at a general pediatric clinic, 7 records were well-child visits for new patients 
and 58 records were well-child visits for established patients. 
Clinical Practice Guideline Adherence  
Clinical practice guideline (CPG) adherence improved significantly after implementation 
of the educational intervention. While adherence at this general pediatric clinic is still relatively 
low compared to what the American Academy of Pediatrics (AAP) and NHLBI would like it to 
be, it is significantly higher than the 2.5%-3.2% national average of adherence reported by the 
Journal of American Medical Association (JAMA) in 2016 (Lozano et. al, 2016).  
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There is a total of 25 advanced practice providers who perform well-child checks at a 
general pediatric clinic. Eleven of the 25 providers (44%) participated in the educational session 
and anonymous survey. Of the 256 medical records that were reviewed during the pre-education 
period, 44 received dyslipidemia screening (17.2%). During the post-education period, 16 out of 
the 65 medical records reviewed received dyslipidemia screening (24.6%, P=0.1701). 
Dyslipidemia screening rates and adherence to the clinical practice guideline (CPG) improved 
from 17.2% to 24.6%, an increase of 43%, at this general pediatric clinic after the educational 
intervention was implemented. (Refer to Figure C and Table 4).  
Adherence to clinical practice guidelines was also examined after an e-mail serving as an 
educational burst was sent to providers at the clinic three weeks after the start of the study. All 
healthcare providers, regardless of whether they received education, received this e-mail 
reminding them of the evidence-based guidelines and the need to screen. Dyslipidemia screening 
rates increased from 18.75% prior to the e-mail to 26.53% after the e-mail was sent (P=0.7409). 
(Refer to Table 5).  
Healthcare Provider Survey Data Analysis  
Descriptive statistics, including means and standard deviations, were used to summarize 
healthcare provider’s confidence and knowledge in dyslipidemia screening indicated by 
anonymous survey results (Refer to Table 6 for a summary of survey results). The results yielded 
that many healthcare providers do not feel confident in the evidence-based guidelines regarding 
dyslipidemia screening and management in the pediatric primary care population. Furthermore,  
many healthcare providers do not feel comfortable treating dyslipidemia in children between the 
ages of 9 and 11 years. 
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The educational intervention was beneficial in many different ways. As aforementioned, 
there was a 43% increase in dyslipidemia screens after education was given in clinic. In addition, 
81.8% of healthcare providers who participated in the survey strongly agreed that they felt more 
confident in when and how to screen, diagnose, and manage dyslipidemia in children between 
the ages of 9 and 11 years after they received education and were updated on the clinical practice 
guidelines. 
Discussion 
   The overall aim of this study was to assess whether healthcare provider education on 
current evidence-based guidelines regarding dyslipidemia screening in children between the ages 
of 9 and 11 years at annual well-child visits affected screening rates at the primary care clinic. As 
childhood obesity rates continue to threaten to rise over the years, it is of increasing importance 
that advanced practice providers are aware of when to screen children as well as how to interpret 
and manage results.  
Based on current screening rates, healthcare providers are not performing dyslipidemia 
screening as often as recommended. The AAP 2013-2014 Periodic Survey of a national and 
randomly selected sample of practicing AAP physicians found that 68% never/rarely/sometimes 
screen healthy 9- to 11- year olds (De Ferranti, Rodday, et. al, 2017). This project identified that 
current screening rates at this primary care setting prior to the intervention was similar to the 
national rate. Overall, the study results and data analysis reveal that providing healthcare 
providers with education increases screening rates.  
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Limitations 
 There were a few limitations identified in this study that could be improved for future 
studies down the road. The first limitation identified was the length of the study. Due to time 
constraints with IRB approval and the end of the semester, the study was only conducted over a 
6-week time frame. Perhaps if the length of the study was longer, results would be more 
accurately depicted.  
 A second limitation had to do with the sample size of medical records reviewed. There 
were significantly more medical records reviewed in the 3-month pre-education period than there 
were in the 6-week post-education time frame. Since the pre-education period occurred over the 
course of the summer, there was an influx of annual well-child exams before the start of the 
school year. The post-education frame occurred once school was in session meaning that a many 
children between the ages of 9 and 11 years had already received their annual exam for the year. 
Perhaps if the pre- and post-education time periods were at the same time of the year, screening 
results would be better analyzed.  
 To assess whether or not a child received dyslipidemia screening, information technology 
conducted a chart analysis that assessed whether or not a specific box was checked in AEHR 
under age-appropriate screenings. This box identified whether screening was either performed or 
ordered at this visit. There is not a corresponding box that healthcare providers could check if a 
child has already received dyslipidemia screening between the 9 to 11-year age range or at a 
separate clinic. Therefore, the results could be falsely skewed.  
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 Lastly, healthcare provider and patient demographics were not reported in this study to 
keep data confidential and private. While this safeguarded privacy, it also didn’t allow for 
analysis of factors that may affect screening rates.  
Recommendations for Future Studies 
Recommendations for future studies include providing more continuing education to 
healthcare providers in practice. While this study was specific to a pediatric primary care clinic, 
family care clinics would also benefit greatly from education on current pediatric evidence-based 
guidelines since family medicine providers also see pediatric patients. Incorporating screening 
reminders within charting systems is a tool that needs to be implemented to increase screening 
rates. This is a simple and cost-effective intervention that could drastically increase adherence to 
clinical practice guidelines. 
Another recommendation for future studies is to expand to multiple different ambulatory 
clinic sites to increase sample size and draw results from a number of different settings. Lastly, 
future studies should consider reasons why healthcare providers are not performing dyslipidemia 
screening. From that information, researchers will be able to tell what is causing this wide gap in 
practice and whether it’s due to a lack of knowledge, cost standpoint, parental refusal, or 
insurance coverage.  
Conclusion 
 The overall goal of my project was to increase screening rates of dyslipidemia in all 
children between the ages of 9 and 11 years at a primary care pediatric clinic. Throughout the 
course of the six-week study, screening rates improved by 43%. Not only that, but 81.8% of 
healthcare providers felt that they benefited from the educational intervention and now feel more 
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confident and knowledgeable in screening, diagnosing, and managing dyslipidemia in the 
primary care setting. The educational intervention implemented in this study promoted evidence-
based care and provided patients with the best quality preventive care. 
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ICD-10 Codes Diagnosis Definition CPT Code Diagnosis Definition 
Z00.121 New and/or 
Established Patient 
Well-Child Exam 
99383 New Patient Well-
Child Exam Late 
Childhood (Age 5-
11 years) 
Z00.129 New and/or 
Established Patient 
Well-Child Exam 
99393 Established Patient 
Well-Child Exam 
Late Childhood 
(Age 5-11 years) 
 
 
 
 
 
 
 
 
 
Table 1. Inclusion Criteria List of Annual Well-Child Exam ICD-10 and CPT Codes 
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Category 
Acceptable 
mg/dL (mmol/L) 
Borderline 
mg/dL (mmol/L) 
HighΔ 
TC <170 (4.4) 170 to 199 (4.4 to 5.2) ≥200 (5.2) 
LDL-C <110 (2.8) 110 to 129 (2.8 to 3.3) ≥130 (3.4) 
Non-HDL-C <120 (3.1) 120 to 144 (3.1 to 3.7) ≥145 (3.8) 
ApoB <90 (2.3) 90 to 109 (2.3 to 2.8) ≥110 (2.8) 
TG 
• 0 to 9 years <75 (0.8) 75 to 99 (0.8 to 1.1) ≥100 (1.1) 
• 10 to 19 years <90 (1 mmol/L) 90 to 129 (1 to 1.5) ≥130 (1.5) 
Category Acceptable Borderline LowΔ 
HDL-C >45 (1.2) 40 to 45 (1 to 1.2) <40 (1) 
ApoA-1 >120 (3.1) 115 to 120 (3 to 3.1) <115 (3) 
TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein; ApoB: apolipoprotein B; 
ApoA-1: apolipoprotein A-1; TG: triglycerides. 
Table adapted from UpToDate retrieved at 
https://www.uptodate.com/contents/image?imageKey=PEDS%2F68183&topicKey=PEDS%2F16972&search=dyslipidemia%20
screening%20in%20children&rank=1~150&source=see_link  
 
 
 
 
 
Table 2. Definition of Lipid Levels in Children from the 2011 Expert Panel Integrated 
Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents 
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 Strongly Disagree Disagree Agree Strongly Agree 
All children 
between the ages 
of 9-11 years who 
present for an 
annual exam 
should be screened 
for dyslipidemia. 
    
I use the evidence-
based guidelines 
regarding 
dyslipidemia 
screening and 
management in the 
pediatric primary 
care population 
when performing 
well-child checks.  
 
    
I know when and 
how to screen for 
dyslipidemia in 
children between 
9-11 years in the 
pediatric primary 
care setting. 
    
I know how to 
diagnose 
dyslipidemia in 
children between 
9-11 years in the 
pediatric primary 
care setting. 
    
Table 3. Provider Confidence in Screening for and Treating Dyslipidemia in 9- to 11-year-
olds at a Pediatric Primary Care Clinic 
 19 
 
I know how to 
manage 
dyslipidemia in 
children between 
the ages of 9-11 
years in the 
pediatric primary 
care setting. 
    
The education 
received today was 
helpful in regards 
to knowing when 
and how to screen, 
diagnose, and 
manage 
dyslipidemia in 
children between 
the ages of 9 and 
11 years. 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 20 
 
Table 4. Percentage of Dyslipidemia Screenings Pre- and Post- Education 
 
 
Pre- and Post- Education 
Time Screened 
0 1 Total
Pre 212
82.81
44
17.19
256
 
Post 49
75.38
16
24.62
65
 
Total 261 60 321
Statistic DF Value Prob
Chi-Square 1 1.8819 0.1701
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Table 5. Percentage of Dyslipidemia Screenings Pre- and Post- Educational Burst E-mail 
Educational Burst E-Mail 
Time Screened 
0 1 Total
1 13
81.25
3
18.75
16
 
2 36
73.47
13
26.53
49
 
Total 49 16 65
Fisher’s Exact Test 
Table Probability (P) 0.2269
Two-sided Pr <= P 0.7409
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Table 6. Summary of Healthcare Provider’s Confidence and Knowledge in Screening and 
Managing Dyslipidemia (N = 11) 
Question Mean (SD) 
All children between 9-11 years who present for 
an annual well-child exam should be screened for 
dyslipidemia 
3.6 (0.5) 
I use the evidence-based guidelines regarding 
dyslipidemia screening when I perform well-child 
checks 
3 (0.8) 
I know when and how to screen for dyslipidemia 3.5 (0.7) 
I know how to diagnose dyslipidemia  3.2 (0.8) 
I know how to manage dyslipidemia   2.7 (0.8) 
The education received was helpful in regards to 
knowing  when and how to screen, diagnose, and 
manage dyslipidemia in children between the ages 
of 9 and 11 years 
3.8 (0.4) 
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Title of Project 
Dyslipidemia Screening in Children between 9 and 11 Years in a Pediatric Primary Care Clinic: 
An Evidence-Based Approach. 
Purpose 
The purpose of this project is to examine the outcome of healthcare provider education on the 
incidence of dyslipidemia screening in a pediatric primary care clinic. The rates of dyslipidemia 
screening will be examined prior to providing education as well as afterwards through a 
descriptive pre and post design. The overall goal of my project is to increase screening rates of 
dyslipidemia at a general pediatric clinic.  
Objectives 
#1: Determine baseline dyslipidemia screening rates at the clinic prior to initiating education. 
#2: Examine dyslipidemia screening rates after education has been given to staff at 1-, 4- and 6- 
weeks. 
#3: Measure healthcare provider’s confidence and knowledge in both screening for and 
managing dyslipidemia according to evidence-based guidelines.   
Fast Facts 
 Dyslipidemia is a known risk factor for CVD that manifests during childhood and 
adolescence  
 Dyslipidemia in children is characterized by disorders of lipoprotein metabolism that 
result in the following abnormalities: high total cholesterol, high low-density lipoprotein 
cholesterol, high triglycerides, and low high-density lipoprotein cholesterol.  
 20% of children in the United States between the ages of 6 & 19 years have adverse 
levels of one or more lipid value and often exhibit no signs or symptoms  
  It is estimated that 50% of children with abnormal serum lipoprotein values will 
continue to have elevated lipid levels into adulthood 
 Approximately 100,000 children under the age of 17 and 400,000 adolescents between 
the ages of 17 & 21 would qualify for statin therapy in the United States based on the 
current NHBLI and AAP recommendations 
 An analysis of National Health and Nutrition Examination Survey (NHAMES), it was 
found that 14% of youths who were normal weight, 22% of youths who were 
overweight, and 43% of youths who were obese had adverse lipid levels 
Figure A: Educational Handout for Healthcare Providers at a General Pediatric 
Clinic 
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AAP Practice Recommendation for Pediatric Primary Care 
The American Academy of Pediatrics (AAP) in conjunction with the NHLBI Expert Panel on 
Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and 
Adolescents endorse that all children between the ages of 9 and 11 years undergo dyslipidemia 
screening before the onset of puberty 
Why Screen? 
Through early identification of dyslipidemia, a child’s lipid profile can be improved through 
lifestyle modifications or medication which reduces their risk of developing premature 
atherosclerosis and CVD in the future 
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To Providers at a general pediatric clinic,  
My name is Meredith Toms and I am a Graduate DNP Student at the University of 
Kentucky. As many of you may know, I am conducting my final DNP project that examines 
dyslipidemia screening rates in children between the ages of 9-11 years following an education 
session that has previously been given. This is a friendly reminder to be screening all children 
between the ages of 9 and 11 years who present to the clinic for a well-child check.  
The American Academy of Pediatrics (AAP) in conjunction with the NHLBI Expert 
Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and 
Adolescents endorse that all children between the ages of 9 and 11 years undergo dyslipidemia 
screening before the onset of puberty. Through early identification of dyslipidemia, a child’s 
lipid profile can be improved through lifestyle modifications or medication which reduces their 
risk of developing premature atherosclerosis and CVD in the future.  
Thank you for taking the time to read this and for taking such good care of all kids seen 
at this general pediatric clinic! If you have questions about the study, please feel free to ask; my 
contact information is given below. 
Sincerely, 
Meredith Toms, RN, BSN, Graduate DNP Student  
University of Kentucky 
513-600-6401 
mrco225@uky.edu 
 
 
 
 
 
 
 
Figure B: Educational burst sent to healthcare providers at a General Pediatric 
Clinic
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Figure C: Graph of Dyslipidemia Screening Pre- and Post- Healthcare Provider 
Education 
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